Results 41 to 50 of about 820 (140)

Cuantificación plasmática de emicizumab

, 2022
El emicizumab (Hemlibra®, Roche) es un anticuerpo monoclonal IgG4 bi-específico, recombinante y humanizado, con afinidad por el FIXa y el FX, mimetizando la función del FVIIIa.
Annetta, E, Frontroth, J, Hepner, M, Sueldo, Emanuel   +3 more
core  

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. [PDF]

, 2020
INTRODUCTION Emicizumab (Hemlibra®, Hoffmann-La Roche, Switzerland) is now available for haemophilia A patients with or without factor VIII inhibitors.
Gerber, B., Hegemann, Inga, Korte, W., Kremer Hovinga, Johanna A, Johanna A. Kremer Hovinga, Kremer Hovinga, J.A., Manuela Albisetti, Angelillo-Scherrer, A., Wolfgang Korte, Walter A. Wuillemin, Kremer Hovinga, Johanna A., Wuillemin, W.A., Studt, J.D., Studt, Jan-Dirk, Alberio, Lorenzo, Alberio, L., Dimitrios A. Tsakiris, Casini, A., Angelillo-Scherrer, Anne, Lorenzo Alberio, Maria Martinez, Tsakiris, Dimitrios A, Anne Angelillo-Scherrer, Lars M. Asmis, Tsakiris, D.A., Pierre Fontana, Albisetti, Manuela, Asmis, L.M., Graf, Lukas, Angelillo, Anne, Lukas Graf, Albisetti, M., Gerber, Bernhard, Bernhard Gerber, Martinez, Maria, Casini, Alessandro, Alessandro Casini, Inga Hegemann, Graf, L., Jan-Dirk Studt, Hegemann, I., Fontana, P., Asmis, Lars M, Fontana, Pierre, Korte, Wolfgang, Martinez, M., Wuillemin, Walter A   +46 more
core   +1 more source

Validación de un método para la cuantificación plasmática de emicizumab

, 2023
Introduction: Emicizumab (Hemlibra®, ROCHE) is a bispecific, recombinant and humanized IgG4 monoclonal antibody, that mimics the function of FVIIIa. Its subcutaneous administration is effective and safe in preventing bleeding in patients with severe ...
Annetta, E, Sueldo, R.E., Frontroth, J.P., Bianco, B, Hepner, M, Cervio, C, Sciuccati, G   +6 more
core  

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis

Research and Practice in Thrombosis and Haemostasis
Background: Recurrent joint bleeding in people with hemophilia A (PwHA) can cause hemophilic arthropathy, resulting in limited movement and chronic pain.
Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami   +11 more
doaj   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

Emicizumab [PDF]

Reactions Weekly, 2020
  +5 more sources

Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa (EFA) is an ultra–extended half‐life factor VIII (FVIII) developed to address limitations of conventional prophylaxis in haemophilia A. Although the XTEND trials reported low interindividual pharmacokinetic (PK) variability, real‐world data remain important to better characterize PK profiles across patient ...
Laurent Sattler, Agathe Herb, Léa Pierre, Jordan Wimmer, Manon Dolt, Olivier Feugeas, Dominique Desprez   +6 more
wiley   +1 more source

Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea

, 2021
Aims: Haemophilia A patients with factor VIII inhibitors (HAPI) experience frequent spontaneous bleeding, approximately once a week, and require expensive bypassing agent (BPA) treatments to control bleeding over their lifetime.
한정우
core   +1 more source

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China

Frontiers in Pediatrics, 2022
BackgroundAs a new non-factor therapy for hemophilia A (HA), real-world study of emicizumab is still scarce. This study aimed to investigate the real-world use of emicizumab in Chinese boys with HA.MethodsPatients with moderate or severe HA were enrolled
Guoqing Liu, Kun Huang, Gang Li, Yingzi Zhen, Zhengping Li, Zhenping Chen, Runhui Wu   +6 more
doaj   +1 more source

Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study

Haemophilia, EarlyView.
ABSTRACT Background Despite effective bleed prevention with Emicizumab, pain remains a relevant clinical burden in adults with severe haemophilia A (sHA). A multidimensional assessment is needed to better characterize contemporary haemophilia‐related pain.
Ilenia Lorenza Calcaterra, Sofia Donnarumma, Guido D'Errico, Carmine De Luca, Chiara Caputo, Paola Ciciola, Ernesto Cimino, Matteo Di Minno   +7 more
wiley   +1 more source